Pharmaceutical sponsor
Biohaven Therapeutics Ltd. Clinical Trials
Studies where Biohaven Therapeutics Ltd. is the lead sponsor: its pipeline by phase, what is enrolling now and where. Studies it supports as a collaborator are in the search.
In numbers
Open to volunteers: recruiting, not yet recruiting or enrolling by invitation. Active adds studies under way that have stopped recruiting.
Open to volunteers
All 9Graves' Disease
An Open-Label Study to Determine if BHV-1300 is Safe in Adults With Graves' Disease
To study the long-term safety and tolerability of BHV-1300
- Trial name
- NCT07901244
- Testing
- BHV-1300
- Volunteers
- 356 people
- Sponsor
- Biohaven Therapeutics Ltd.
Parkinson Disease
A Study to Determine if BHV-8000 is Effective, Safe and Tolerable as a Treatment for Adults Living With Early Parkinson's Disease
A study to determine if BHV-8000 is efficacious, safe and tolerable in adults diagnosed with early Parkinson's disease. The study will consist of a 48-week double-blind treatment phase followed by a 48-week open-label phase.
- Trial name
- NCT06976268
- Testing
- BHV-8000 10mg, BHV-8000 20 mg
- Where
- 25 sites in United States
- Volunteers
- 550 people
- Sponsor
- Biohaven Therapeutics Ltd.
Graves Disease
Study to Determine if BHV-1300 is Effective and Safe in Adults With Graves' Disease
The purpose of this study is to evaluate the efficacy and safety of BHV-1300 in adult participants with Graves' disease who are actively hyperthyroid
- Trial name
- NCT07661056
- Testing
- BHV-1300
- Where
- 56 sites in United States, Canada and 1 more
- Volunteers
- 300 people
- Sponsor
- Biohaven Therapeutics Ltd.
Solid Tumor
A Phase 1/2 Study of BHV-1510 (Previously PBI-410) in Advanced Solid Tumors
This is a Phase 1/2, first in human (FIH), open-label, multicenter study of BHV-1510 monotherapy and in Combination with Cemiplimab in participants with previously treated, advanced solid tumors.
- Trial name
- NCT06384807
- Testing
- BHV-1510, Cemiplimab
- Where
- 17 sites in United States
- Volunteers
- 500 people
- Sponsor
- Biohaven Therapeutics Ltd.
Graves Disease
Study of BHV-1300 in Graves' Disease
The purpose of this study is to determine if BHV-1300 is a safe treatment in participants with Graves' Disease and to explore its effect on disease-specific biomarkers.
- Trial name
- NCT06980649
- Testing
- BHV-1300
- Where
- 18 sites in United States, Australia
- Volunteers
- 15 people
- Sponsor
- Biohaven Therapeutics Ltd.
Solid Tumor
A Phase 1 Study of BHV-1530 in Advanced Solid Tumors
This is a Phase 1, first in human (FIH), Open-Label, Dose Escalation, Dose Expansion and Dose Optimization Study of BHV-1530 as Monotherapy and in Combination with Other Anti-Cancer Agents in Adult Participants with Advanced or…
- Trial name
- NCT06874335
- Testing
- BHV-1530, Cemiplimab
- Where
- 17 sites in United States
- Volunteers
- 140 people
- Sponsor
- Biohaven Therapeutics Ltd.
IgA Nephropathy
Study of BHV-1400 in IgA Nephropathy
The purpose of this study is to determine if BHV-1400 is a safe and tolerable treatment in participants with IgA Nephropathy (IgAN).
- Trial name
- NCT07054684
- Testing
- BHV-1400
- Where
- 15 sites in United States, United Kingdom
- Volunteers
- 20 people
- Sponsor
- Biohaven Therapeutics Ltd.
IgA Nephropathy
A Study to Determine if BHV-1400 is Effective and Safe in Adults With IgA Nephropathy
The purpose of this study is to determine if BHV-1400 is effective and safe in the treatment of IgA Nephropathy. Participants will be randomized in a 2:1 ratio to receive either BHV-1400 or placebo.
- Trial name
- NCT07642050
- Testing
- BHV-1400
- Volunteers
- 420 people
- Sponsor
- Biohaven Therapeutics Ltd.
Focal Epilepsy
Long-term Safety and Tolerability of BHV-7000
A study to determine if BHV- 7000 is safe and tolerable in adults with refractory focal onset epilepsy
- Trial name
- NCT06443463
- Testing
- BHV-7000
- Where
- 283 sites in United States, Argentina and 25 more
- Volunteers
- 660 people
- Sponsor
- Biohaven Therapeutics Ltd.